Drug Trial Radar · NCT07235137
A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults
Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Oct 16, 2025
Primary completion
Nov 21, 2025
Study completion Nov 21, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to learn how the study medicine called Ibuzatrelvir is taken up into the blood in healthy Chinese adults.
Conditions
- Healthy Participant
Interventions
IbuzatrelvirDrug
Ibuzatrelvir will be given by mouth to adult Chinese healthy volunteers
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax)Time frame: up to Day 3
- AUCinfTime frame: up to Day 3
- Terminal phase half-life (t½)Time frame: up to Day 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.